Pradaxa is a new oral anticoagulant under development by Boehringer Ingelheim. It has a rapid onset and offset of action and predictable anticoagulation action, eliminating the need for coagulation monitoring.
-
Venous thromboembolism is the third most common cardiovascular disease after... -
Venous thromboembolism can lead to deep vein thromboses and pulmonary embolisms. -
Patients undergoing major orthopaedic surgery are at an especially high risk... -
In clinical use for some 50 years, the vitamin K antagonist warfarin remains... -
Pradaxa is a new oral anticoagulant under development by Boehringer Ingelheim.
